Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Profit After Tax (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Profit After Tax over the past 16 years, most recently at -$1.1 million for Q2 2025.

  • For Q2 2025, Profit After Tax rose 83.81% year-over-year to -$1.1 million; the TTM value through May 2025 reached -$38.7 million, down 446.83%, while the annual FY2025 figure was -$38.7 million, 514.93% down from the prior year.
  • Profit After Tax for Q2 2025 was -$1.1 million at Lifecore Biomedical, Inc. \De\, up from -$14.8 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $14.8 million in Q1 2024 and troughed at -$38.5 million in Q4 2021.
  • A 5-year average of -$10.9 million and a median of -$9.6 million in 2021 define the central range for Profit After Tax.
  • On a YoY basis, Profit After Tax climbed as much as 211.03% in 2023 and fell as far as 919.23% in 2023.
  • Year by year, Profit After Tax stood at -$38.5 million in 2021, then surged by 66.71% to -$12.8 million in 2022, then soared by 211.03% to $14.2 million in 2023, then tumbled by 146.22% to -$6.6 million in 2024, then surged by 82.54% to -$1.1 million in 2025.
  • Business Quant data shows Profit After Tax for LFCR at -$1.1 million in Q2 2025, -$14.8 million in Q1 2025, and -$6.6 million in Q4 2024.